Critiquing: Doctor accused of selling false hope to families (USA TODAY NEWS, NATION, Liz Szabo, USA TODAY)

20131116-002847.jpg
I gave Liz Szabo and USA TODAY the chance to act like a Spike Lee joint and “Do the Right Thing”, the same day their article came out [1]

I gave them the opportunity to prove that their article was a legitimate piece of journalism with some semblance of integrity, and NOT just akin to one of “The Skeptics™ phoned-in “rubber-stamped” yellow journalism hit pieces

Instead, it seems that Liz Szabo and / or USA TODAY decided to act as if they had rolled a Spike Lee joint

I sent an e-mail with 2 editorial corrections, and only one (correcting Lisa Merritt’s comment
link from taking the reader to the 1999 Mayo Clinic report instead of to her comments), was corrected [2]

The 2nd correction which they #FAILED to do, earns them well deserved INSOLENCE
——————————————————————
The article claims:
——————————————————————
Burzynski, 70, calls his drugs “antineoplastons” and says he has given them to more than 8,000 patients since 1977.”
——————————————————————

20131116-004037.jpg
——————————————————————
However, if you select the “8,000 patients” link, the referenced page does NOT indicate that at all [2]
——————————————————————

20131116-064344.jpg
——————————————————————
It advises:
——————————————————————
“That same year, Dr. Burzynski founded his clinic in Houston where he’s since treated over 8,000 patients.” [3]
——————————————————————

20131116-064326.jpg
——————————————————————
Nowhere does it indicate that he “treated 8,000 patients” with antineoplastons
——————————————————————

20131116-064409.jpg
——————————————————————
The question that Liz Szabo and USA TODAY should answer, is:

1. Who is your “fact-checker”, and
2. are they smarter than a 5th grader ?
——————————————————————
In fact, Burzynski’s 2002 Securities and Exchange Commission (SEC) filing advises:

” … in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene targeted therapy, immunotherapy and hormonal therapy in response to FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston clinical trials” [4]
——————————————————————
The article continues:
——————————————————————
“Individual success stories can be misleading, said Arthur Caplan, a professor and head of the division of bioethics at NYU Langone Medical Center”
——————————————————————
The question Arthur Caplan should be asking is:

Why has the United States Food and Drug Administration required Burzynski’s clinical trial patients to fail conventional therapies; such as surgery, chemotherapy, and radiation, BEFORE they are allowed to be treated with antineoplaston therapy ?

If the F.D.A. did NOT impose these restrictions upon Burzynski’s clinical trials, then the question Arthur Caplan raises would be moot
——————————————————————
The article quotes Dr. Jan Buckner as saying:
——————————————————————
“When I hear a story that is way out of the norm, the first question I ask is,

‘OK, is the diagnosis even correct?‘ ”

Buckner said”

“If the diagnosis wasn’t right to start with, it doesn’t matter what the treatment was.”

“Brain tumors are notoriously difficult to diagnose, Buckner says”

“When dealing with rare brain cancer, doctors may disagree about how to interpret imaging results up to 40% of the time”
——————————————————————
I wonder if Dr. Jan Buckner would agree with David Gorski; who is a BREAST cancer oncology specialist, and NOT a BRAIN cancer oncology specialist, who has the presumptiveness to speculate that 3 different medical opinions could have misdiagnosed Tori Moreno in August 1998; who was diagnosed with a very large tumor, about 3 inches in the largest diameter and located in the brain stem, which was too risky for surgery, and about which her parents were told by ALL 3, that Tori’s brain cancer was fatal and, she would die in a few days or at the most, 2-6 weeks, and that there was nothing that could be done, and was finally put on Burzynski’s antineoplaston therapy in October, when she was about 3 ½ months old, and in such condition that they were afraid that she might die at any time, David H. Gorski, M.D., Ph.D., FACS; who claims, “I do know cancer science” , has the audacity, because of his “book learnin'” has the temerity to postulate his “science-based medicine theory” that Miller’s Children at Long Beach Memorial misdiagnosed Tori Moreno’s inoperable stage 4 BSG

David Gorski has the gall to profer that City of Hope misdiagnosed Tori Moreno’s inoperable stage 4 brain stem glioma

David Gorski has the chutzpah to pontificate that Dr. Fred Epstein in New York misdiagnosed Tori Moreno’s inoperable stage IV brainstem glioma [5]
——————————————————————
The article then quotes Peter Adamson, chair of the Children’s Oncology Group:
——————————————————————
“But these therapies may have delayed benefits, taking weeks or months to shrink a tumor

“So patients treated by Burzynski may credit him for their progress, just because he was the last doctor to treat them, says Peter Adamson, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer

Conventional cancer treatment can also cause tumors to swell temporarily, due to inflammation

“A patient who isn’t familiar with this phenomenon may assume her tumor is growing

“When that swelling subsides, patients may assume it’s because of Burzynski, Adamson says”
——————————————————————
This is laughable

In support of this “phenomenon” , the article provides a link to a Canadian web-site [6]

The site posits:
——————————————————————
“RT/TMZ is now widely practiced and the standard of care for appropriately selected patients, we are learning more about the consequences of RT/TMZ”

“One phenomena, termed Pseudo-Progression (psPD)…”
——————————————————————
The problem is that this only applies to “Glioblastoma Multiforme (GBM)”, and the article provides NO proof whatsoever, that any of Burzynski’s “Glioblastoma Multiforme (GBM)” patients have taken “RT/TMZ”
——————————————————————
Additionally, the site cites the reference as:

Sanghera, Perry, Sahgal, et al., “Sunnybrook Health Sciences Odette Cancer Centre” (in press, Canadian Journal of Neuroscience)

(“In press” refers to journal articles which have been accepted for publication, but have not yet been published)

However, the journal article in question was published 1/2010, so it has NOT been “in press” for over 3 years and 7 months [7]

Get your act together, aye, Canada !
——————————————————————
The article rants and raves on and on about FDA inspection reports from as far back as 1998, but at least they did quote Richard A. Jaffe:

“In Burzynski’s defense, Jaffe notes that inspection reports represent preliminary findings

“The FDA has not yet issued final conclusions”
——————————————————————
The article posts this ridiculous claim:
——————————————————————
“Yet the National Cancer Institute says there is no evidence that Burzynski has cured a single patient, or even helped one live longer
——————————————————————
That’s NOT what this seems to suggest [8]
——————————————————————
Then the article quotes pediatric oncologist Peter Adamson, a professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia, in what will no doubt soon be known as a “classic”:
——————————————————————
“He’s a snake oil salesman,” says pediatric oncologist Peter Adamson, a professor of pediatrics and pharmacology at Children’s Hospital of Philadelphia”
——————————————————————
All I’d like to know is, which rock did this clown crawl out from under ?

Dr. Adamson, please advise which “snake oil” has been granted Orphan Drug Designation (“ODD”) from the United States Food and Drug Administration [9], and which “snake oil” has been approved for, and used in, phase III clinical trials ? [10]
——————————————————————
Q: Is it, it the phase 2 trial is finished ?

A: “Mhmm”

Q: but they’re still accepting people ?

A: “Yeah”

Q: on more like a special ?

A: Special basis, and, um, sometimes compassionate grounds

A: “(compassion exception)”

A: “Uh, exceptions

Q: That’s normal ?

A: “Yes”
“So”

A: “(Yes I guess it is a funding issue ?)”

Q: Right

A: “(Like FDA, during the 2nd phase of clinical trials they found the data to be, real, real one, and they gave him the ok to go for 3rd phase of clinical trials, but just to go through this process you would probably need $100,000)”
——————————————————————

20131116-164617.jpg

20131021-200529.jpg

20131021-200553.jpg
——————————————————————
Oh, wait !!

Dr. Adamson, when you say “snake oil”, I take it you are referring to the low-dose chemotherapy that Burzynski uses ?

Dr. Adamson, do you know what a “hack” is ?
——————————————————————
In regards to the Merritt’s, the article has:
——————————————————————
“The couple say that Burzynski misled them about the type of treatment that would be offered, as well as the cost”

My questions about the Merritt’s are:

1. Where is their complaint to the Texas Medical Board ?

2. Where is their lawsuit ? Couldn’t they find an attorney to take their case pro bono ?
——————————————————————
The article continues:
——————————————————————
“Yet even Jaffe has acknowledged that the trialnow in its 17th year — was more about politics than science”

“In his 2008 memoirs, Galileo’s Lawyer, Jaffe called it “a joke.”

“”It was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment,” Jaffe said
——————————————————————
What Liz Szabo and her friends at USA TODAY fail to let the readers know, is that this only applied to one trial:
——————————————————————
Burzynski’s lawyer is obviously referring to the CAN-1 clinical trial mentioned in Burzynski’s 11/25/1997 Securities and Exchange Commission (SEC) filing [11]
——————————————————————
One trial that is retrospective is CAN-1 Clinical Trial
——————————————————————
CAN-1 PHASE II STUDY OF ANTINEOPLASTONS A10 AND AS2-1 IN

PATIENTS WITH REFRACTORY MALIGNANCIES

133 patients
——————————————————————
Clinical trial of patients treated by Dr. Burzynski through 2/23/1996
——————————————————————
FDA has indicated it will not accept data generated by this trial since it was not a wholly prospective one
——————————————————————
The article continues in the same vein:
——————————————————————
“In an interview, Burzynski said developing new drugs is complex and takes time

“Yet the FDA has approved 108 cancer drugs since Burzynski began his trial”
——————————————————————
Ms. Szabo and “pals” conveniently “forgets” to educate their audience that Burzynski was using Fleming’s One-sample multiple testing procedure for phase II clinical trials [13], which requires that if the 1st 20 patients meet certain criteria, 20 additional patients are added [14]
——————————————————————
“Well, we cannot publish until the time is right” (laughs)

Yeah

“If you would like to publish the results of, of a
10 year survival, for instance”

Mmm

“Which we have
Nobody has over 10 year survival in
malignant brain tumor, but we do, and if you like to do it right, it takes time to prepare it, and that’s what we do now
What we publish so far
We publish numerous, uh, publications which were, interim reports when we are still continuing clinical trials
Now we are preparing, a number of publications for final reports
[15]
——————————————————————
Then Fran Visco, president of the National Breast Cancer Coalition makes an outlandish statement, which is quoted in the article:
——————————————————————
“Fran Visco, president of the National Breast Cancer Coalition, describes the FDA’s tolerance of Burzynski as “outrageous.”

“They have put people at risk for a long time,” says Visco, an attorney and breast cancer survivor

“That’s completely unacceptable”

“How can anyone look at these facts and believe that there is a real clinical trial going on … rather than just using the FDA and the clinical trial system to make money?”
——————————————————————
I have a suggestion for Ms. Visco

Take your hypocrisy and ask the American Cancer Society if they are still engaged in this kind of activity:

1. AMERICAN CANCER SOCIETY: More Interested In Accumulating Wealth Than Saving Lives [15]

2. National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest [16]
——————————————————————
Then, ask the American Cancer Society, why is it that 10 years ago, estimated breast cancer deaths were expected to be 39,800 (15%), and this year it was 39,620 (14%), which is ONLY 180 LESS than 10 years ago ?
——————————————————————
Estimated Breast Cancer Deaths (Women)-USA
——————————————————————
2013☝39,620 (14%)
2012👇39,510 (14%)
2011👇39,520 (15%)
2010👇39,840 (15%)
2009👇40,170 (15%)
2008☝40,480 (15%)
2007👇40,460 (15%)
2006☝40,970 (15%)
2005👇40,410 (15%)
2004☝40,110 (15%)
2003☝39,800 (15%)
2002
39,600 (15%)
—————————————————————–
American Cancer Society Cancer Facts & Figures (2002-2013)
—————————————————————–
And then ask the American Cancer Society, why is it that 10 years ago, the estimated NEW breast cancer cases were expected to be 211,300 (32%), and this year it was 232,340 (29%), which is 21,340 MORE than it was 10 years ago ?
——————————————————————
Estimated New Breast Cancer (Women) – USA
——————————————————————
2013☝232,340 (29%)
2012👇226,870 (29%)
2011☝238,480 (30%)
2010☝207,090 (28%)
2009☝192,370 (27%)
2008☝182,460 (26%)

2007👇178,480 (26%)
2006☝212,920 (31%)
2005👇211,240 (32%)
2004☝215,900 (32%)
2003☝211,300 (32%)
2002
_-_203,500 (31%)
—————————————————————–
American Cancer Society Cancer Facts & Figures (2002-2013)
——————————————————————
And after that, ask Susan G. Komen how much is spent on legal action to protect her brand, compared to how much is spent on breast cancer research and prevention ?
——————————————————————
Visco, the breast cancer advocate

“I do NOT know why it took YOU so long.”
——————————————————————
The article continues with:
——————————————————————
“Yet hypernatremia is one of antineoplastons’ most common side effects, known to doctors for two decades”
——————————————————————
Yet, “The Skeptics™” refuse to discuss:
——————————————————————
2/13/2013 – The frequency, cost, and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center

Over 3 month period in 2006 re 3,446 patients, most of the hypernatremia (90 %) was acquired during hospital stay [19]

Division of Internal Medicine, UT MD Anderson Cancer Center, Houston, TX, USA

Department of General Internal Medicine, University of Texas MD Anderson Cancer Center

Division of Endocrinology, Mayo Clinic
——————————————————————
9/1999 – The changing pattern of hypernatremia in hospitalized children [20]

Department of Pediatrics, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas, USA
——————————————————————
So, after all that, my question for USA TODAY is, does Liz Szabo, Michael Stravato, Jerry Mosemak or Robert Hanashiro have a
journalism degree ?

Because if any of them do, the institution they obtained it from most be so proud of this piece of “fish wrap” you produced

Thank you, USA TODAY, for censoring my 18 comments

I guess you must be (“intellectual”) cowards

At least Forbes had the GRAPEFRUITS to post some of my comments
——————————————————————
You’ve just been served, INSOLENTLY
——————————————————————
USA TODAY, GONE TOMORROW
——————————————————————

20131116-084820.jpg

20131116-085357.jpg

20131116-084833.jpg

20131116-084847.jpg

20131116-084909.jpg

20131116-084924.jpg

20131116-084937.jpg

20131116-085152.jpg

20131116-085218.jpg

20131116-085311.jpg

20131116-085436.jpg

20131116-085528.jpg

20131116-085550.jpg

20131116-085608.jpg

20131116-085629.jpg

20131116-084804.jpg

20131116-084745.jpg
======================================
REFERENCES:
======================================
[1] – 11/15/2013 – USA TODAY NEWS, NATION
Doctor accused of selling false hope to families
Liz Szabo, USA TODAY
——————————————————————
http://www.usatoday.com/story/news/nation/2013/11/15/stanislaw-burzynski-cancer-controversy/2994561/
======================================
[2] – Mayo Clinic – 1999 – report: Lisa Merritt
——————————————————————
https://www.documentcloud.org/documents/816819-mayo-clinic-1999-report.html
======================================
[3] – 2012 – former Burzynski web-site screenshots, Pg 3 of 62;
——————————————————————
http://www.circare.org/info/bri/burzynski_fdauntitled_promo_2012.pdf
======================================
[4] – 4/26/2013 – Burzynski: FDA requirements that cancer patients utilize more traditional cancer treatment options in order to be eligible to participate in the Company’s Antineoplaston CLINICAL TRIALS:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/26/burzynski-fda-requirements-that-cancer-patients-utilize-more-traditional-cancer-treatment-options-in-order-to-be-eligible-to-participate-in-the-companys-antineoplaston-clinical-trials/
======================================
[5] – 11/14/2013 – Critiquing: Why we fight for patients (Why we fight your patience) TAM 2013, TAM2013, “The Amazing Meeting” 2013 #TAM2013 http://www.theamazingmeeting.com
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/14/tam-2013-tam2013-tam2013-the-amazing-meeting-2013-the-amazing-meeting-httptheamazingmeeting-com-httpwww-theamazingmeeting-com/
======================================
[6] – Phenomenon – Brain Tumour Foundation of Canada
——————————————————————
http://www.braintumour.ca/1649/ask-the-expert-psuedo-progression-gbm
======================================
[7] – Pseudoprogression following chemoradiotherapy for glioblastoma multiforme
Can J Neurol Sci. 2010 Jan;37(1):36-42
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/20169771/
======================================
[8] – 9/19/2013 – Critiquing: National Cancer Institute (NCI) at the National Institutes of Health (NIH) CancerNet “fact sheet” :
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/19/critiquing-national-cancer-institute-nci-at-the-national-institutes-of-health-nih-cancernet/
======================================
[9] – FDA Orphan Drug Designation
——————————————————————
http://www.burzynskiresearch.com/assets/PressRelease_12022008_BZYR(2).pdf
======================================
[10] – 11/7/2013Pete Cohen chats with Sonali Patil, Ph.D., Research Scientist at The Burzynski Clinic:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/07/pete-cohen-chats-with-sonali-patil-ph-d-research-scientist-at-the-burzynski-clinic/
======================================
[11] – 7/9/2013 – Burzynski: The Original 72 Phase II Clinical Trials:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/07/09/burzynski-the-original-72-phase-ii-clinical-trials/
======================================
[12] – 8/21/2013 – Critiquing David H. Gorski, MD, PhD, FACS http://www.sciencebasedmedicine.org/editorial-staff/david-h-gorski-md-phd-managing-editor/
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/08/21/critiquing-david-h-gorski-md-phd-facs-www-sciencebasedmedicine-orgeditorial-staffdavid-h-gorski-md-phd-managing-editor/
======================================
[13] – 2003 – pg. 94
——————————————————————
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf
======================================
[14] – 3/1982 – Biometrics 1982; 38: 143-51
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/7082756/
======================================
[15] – 11/9/2013Pete Cohen chats with Dr. Stanislaw Burzynski – Interview #2:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/09/pete-cohen-chats-with-dr-stanislaw-burzynski-interwiew-2/
======================================
[16] – AMERICAN CANCER SOCIETY: More Interested In Accumulating Wealth Than Saving Lives
——————————————————————
http://www.wnho.net/acs.pdf
======================================
[17] – 9/11/2013 – National Cancer Institute and American Cancer Society: Criminal Indifference to Cancer Prevention and Conflicts of Interest:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/09/11/national-cancer-institute-and-american-cancer-society-criminal-indifference-to-cancer-prevention-and-conflicts-of-interest/
—————————————————————
[18] – 11/13/2013 – The War on Cancer (I don’t think it means, what you think it says it means) #Winning?
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/11/13/httpcancer-orgacsgroupscontentepidemiologysurveilancedocumentsdocumentacspc-036845-pdf/
======================================
[19] – 4/24/2013 – Burzynski: HYPERNATREMIA:
——————————————————————
https://stanislawrajmundburzynski.wordpress.com/2013/04/24/burzynski-hypernatremia/
======================================
[20] – 9/1999 – Pediatrics. 1999 Sep;104(3 Pt 1):435-9
——————————————————————
http://www.ncbi.nlm.nih.gov/pubmed/10469766/
======================================

20131116-002912.jpg

Advertisements

Pete Cohen chats with Sonali Patil, Ph.D., Research Scientist at The Burzynski Clinic

======================================
1/2012Sonali Patil, Ph.D., Research Scientist at The Burzynski Clinic
(18:22) 9/18/2012
======================================
So you, you, you’re a scientist here ?

I’m a scientist here

And, and you work, just with antineoplastons ?

Not necessarily
This is our cell biology lab, and in molecular biology we do basic research on the antineoplastons
Sometimes we also study it in combination with the other, uh, medicines that Dr. Burzynski is interested in
So, but mostly antineoplaston
This is looking at mechanism for action
Trying to understand how it treats the cancer cells, is able to kill the cancer cells without damaging the other cells of the body
So mostly antineoplaston is the target here

And what do you think about
antineoplastons ?

We have found, uh, very interesting, uh, molecular pathways targets that antineoplaston is targeting, working very effectively to kill the cells, um, probably better than many other drugs, because, um, it has multiple targets, and so attacks the cells from many different angles, and is able to kill the cancer cells, more effectively

So, can I ask you, how did you come to work in, th, the Burzynski
the institution ?

Through an advertisement, it was
My position was advertised
I started 8 years ago, and

So ok
So it was advertised

Mhmm

So when you applied for the job, were you aware of the controversy of, (comments to self: learn to talk)
So when, when did you find out ?

Uh, eh, as soon as I joined (laughing)

Oh yeah ?

Few months later
I thought, it’s easy to find
It’s not hard

Of course

It’s not even, uh

Wha, what about any of you other colleagues, that prior to coming here ?
I mean, did they say anything to you, like, you know ?

Well they brought something up
(?) in, uh, uh, being there for him during this trial, my boss, my previous boss was here before me
Uh, so I have a very open picture of it, and it doesn’t bother me
He came up against it and won

Yeah

So that’s a good thing

An, and why do you think, it kinda hasn’t been, kinda lost the word, hasn’t taken off, you know ?
Has the scientific community hasn’t really embraced ?

Well anything that is non-traditional always, you know, takes its own time to get to people
Besides, the traditionalists don’t want it coming out because, uh, it affects, a lot of other things, um, finance, in, in the big Pharma

Right

that is affected by this
So, um, if it, if it were, um, a medicine already with another big company, it probably would already be out in the market by now, but, uh, it’s because it’s one man’s show
He’s fighting against, uh, traditional medicine, big, big centers like M.D. Anderson right here in Houston
So, most people want to believe, uh, what the other doctors, the oncologists, are telling them, because that’s what everybody does
So very few filter out of that and come looking for him, because they’ve lost hope there, and they’ve tried everything else, and they come because; which I wish they wouldn’t, come here as a last resort, you know

Mmm

and, by then, sometimes, uh, enough damage has been done that is sometimes even he cannot cure
It’s not magic
It’s
There’s a logic to the way the medicine works
The science behind it is not, it’s not just a magic bullet
So, and you have to target it at the right time
Catch cancer at the right time

So I have a, friend of my mother’s at home, whose spent, her whole, academic career, 20, 30 years, researching, astrocytomas

Mhmm

And, uh, you know, I did my research, and, I was no doubt that we were coming here
No question
My, my research was more based on people

Excuse me

On people
Talking to people who had been treated, and seeing the results, and then looking at the research afterwards, and she was just saying that “I’ve spent all my years, research, and research, and research, I can’t find anything, that validates, this, this treatment
Now I’m not asking you to comment on what she said, but,

No, validation, validation basically means, uh, proof in scientific community
If you’re not accepted into the scientific community, you’re not going to be able to present that truth, and we go and present at conferences all the time, eh, when it comes to publishing papers, uh, we haven’t been very successful
Dr. Burzynski has published, uh, a lot of data of his patients
So it’s out there

Yeah

If you, if you want to believe it, and you’re looking for it, you’ll find it

Yeah

It’s just, um, it’s not in the mainstream places, because it gets rejected out of there
Um, it’ll probably take some time to get into those spots where everybody else is publishing, and everybody else is talking about it, but it doesn’t mean that it’s not true

So obviously you’re here on a daily basis
So when was the 1st

Last 8years

So the last 8 years
When was the 1st time you actually saw, was it in the dish where you actually saw it ?

Well we see it, we’ve seen it for years before I came here

Yeah, but when was the 1st time you saw it, when you came here yourself and you saw ?

Well we see it every day
Um, we have cancer cells in the lab, that we treat, with the medicine
We see them dying
We see them undergoing a necrosis, which is the cancer deaths, pathway, that most people study and talk about

So

So, it’s happening, it’s happening in front of our eyes everyday
So, we have proof for it
you know (?)
We just have to get it out there, and there’s a, there’s a system to all that

Um

and were trying to, get it through the system, and get it out there

So what, when you 1st realized there is something here, did you not just feel like just shouting from the rooftops and telling everybody?

Well I wasn’t the one who discovered
He did, in the ’80’s

Yeah

and since then he’s been shouting from the rooftop
It’s just, nobody would listen to him

Yeah, yeah

So, you know, we’re just doing the, uh, actually it’s backwards
People usually do, uh, pre-clinical research 1st, because the medicine

Mhmm

goes out and to the patients, and we, we are kind of doing it, the other way around
He already has patient data
He’s been treating people
on this
People, survivors walking around, to tell the story, and now we are being made to understand how it works in the cells
So, it’s, it’s kinda doing, the research, after the trials

Just tell me
One more question
What’s it like
How would you describe Dr. Burzynski ?

I admire his, uh, passion, for what he does
He truly believes in what he does, and to me that’s, that’s a big thing
If you don’t believe in yourself, then nobody else will, and, his memory
He, he has tremendous memory, and, uh, uh, quick thinking
He’s able to piece together stuff, uh, research articles, papers, put together puzzle, come up with a theory
He does that every day, every time I meet him it’s, it’s interesting to me to see how his brain works

you say, in, in the purest sense, he’s a scientist

I think he’s a doctor 1st, but a doctor who’s very, very interested in science, and that’s an important thing, because a lot of, uh, doctors don’t care about the research, and he does
I think, I think his primary aim is to treat patients, mostly

So if there were any type of skeptic, research scientist out there, what would you say to them about what goes on here?

We do, we do, everything that happens in any other lab, anywhere else
I went to school at Houston, ah, so, I know exactly how the labs work
We do exactly what they do

Yeah

Um, we try to write up our papers, and send them to the journals, just like everybody else does
Uh, present at conferences
We try to get our data out there
Um, we’re trying to do our best, just the way everyone else is

I, I suppise trying to do your best it, it, it’s fascinating because you actually have something

Yeah

that really, really does work

Mhmm

I mean, it’s a cure, right ?

We believe it is

It’s a cure for cancer
Not for all cancers
I actually asked Dr. Burzynski

Mhmm

I filmed him the other day and said to him, why do you, specialize in brain tumors ?

Mhmm

Do you know what his answer was ?

What was it ?

He said it’s because it’s the most difficult type of cancer

Well it is if, if you think about it
I don’t think there are many doctors who claim to have survivors, eh, at least in the numbers that he has, to present

Yeah

and, um, I hear that at conferences too when we, were standing around, they will look at the slides, eh, eh, which is a tumor, and they will say: “Well that’s not a tumor,” ye, “it’s just necrosis
It’s just a patch on the skin, and you just cured nothing, and”, uh, all the, “the patient was probably cured from, the therapy that he took elsewhere, you know, the radiation he got 10 years ago”
“That’s probably what cured him,” but, you know, th, those kind of patients will be rejected from other, hospitals, don’t survive, that far enough to, to tell a story

So what is it ?
Just people living in denial ?
Is it fear ?
Is it ?

Fear or denial
I’m going to do what everybody else does
Why, why should I go out and do something different, here ?
Yeah (?)

And, and lastly, you know the, the power the pharmaceutical companies have

Well of course
I mean, but I’m nobody to, comment about that

Yeah, yeah

You know
There’s, there’s a lot going on behind the scenes that we are not even aware of, but this is just what, um, my experience is, when I talk to other doctors at meetings and conferences, and they, you’re immediately dismissed as, oh, you know: “What you’re going to say doesn’t really make any sense because you work for, Dr.

His name has been tarnished
——————————————————————
There’s a lot more, to that, than just, people playing politics, this, this, a whole lot of stuff going on behind there
So, I don’t think it’s, it’s (supression ?) as much, it’s just trying to tell your story, uh, so that somebody would listen and accept it, uh, maybe using, the right channels, going, presenting it in a different way, make it more convincing
All that, would help

So if it, if it was you, in his position, would you not have just given up ?
Or would you

Oh, definitely
We all talk about it all the time, that the amount of determination that he has, most people, would back off and leave, but like I said, he believes in what he does, and that’s what keeps him going

Yeah
As far as publishing is concerned, ’cause a lot of scientist want to see

We’ve tried
We, we, don’t get past the initial screening
We repeatedly send it back to other journals and that’s the process I keep doing all the time
Comes back, I send it back to another journal
Hopefully, one day it will get it

So, let, let, let, let me get this straight, ok ?
You write articles, right ?

Papers

Papers

Mhmm

and you submit them to, medical journals

Mhmm

and then what happens ?

They come back

Why do they come back ?

Sometimes, um, if they get to reviewers, uh, it’s not enough data, or, which I understand
We can work on changing, modifying papers, but, many times they come back, without any reason
They just get rejected, at the 1st, screen itself
So they come back without any reason

And why do you feel that is, in your own humble opinion ?

Wha ? (laughing) not humble opinion
It’s, it’s hard, um, publishing is a tricky game, you know ?
You have to publish once, to get your name in there, and then, they might publish you again, but, uh, with the negative publicity that we already had, and most of the community would look at the name and say: “Oh we, we just don’t want to, want to even read it”
So, it, it doesn’t even get past the 1st screen, because they don’t turn, flip the 1st page even

Ok, so, what you’re saying is that you see things that are published in these journals

Oh yes

And, you see ?

very similar stuff
We try to, we try to do research that is on par, uh, with what everybody else is doing, as far as the techniques, the ana, the data analysis
We, we try to do everything which is the standard for, uh, the research community, but, doesn’t get past

Um, how frustrating must that be for you ?

Mmm, it is (laughing), it is

So do you feel like you’re a party, or you’re trying to get into a party, and knocking on the door, and no one’s letting you in ?

I feel like that at the conferences too because, um, sometimes they come up to your, poster presentations, and, um, they’ll ridicule you right there, while you’re standing there by your presentation

Ok, just last thing, because one of the things I heard

Mhmm

recently, which were, that, uh, there’s some evidence that Dr. Burzynski has from, from the phase 2 clinical trials, showing people who have, uh, glioblastomas who’ve been alive for 10 years

Mhmm

and there’s something there that they want to try and get published

Mhmm

What you’re saying is, that might never get published ?

Well, Dr. Burzynski’s case is different
He has published some of his patient data
I’m talking about the research, uh, the pre-clinical research, the cell culture data, the molecular data
Um, we haven’t had success getting that out, but, he has, he also faces rejection a lot, but he doe, he has managed to get ta, a few publications in

So how does it work ?
If, if you submit something they can
What’s the process ?
They can submit it back ?

That’s not, there’s a review
There’s a whole review board
Um, you can select your reviewers
It goes through couple of cycles of review before it’s, agreed that they will publish it
So,

And in case they say no to publishing it

You can

do you, can you take it somewhere else ?

Yeah, you can take it somewhere else, but, um, but it’s, the peer-reviewed journals that are the ones that you want to get into, you can publish whatever you want, ah, that doesn’t count
That’s why when, somebody who’s of, uh, any significance in science would not even look at those articles if they’re not in a peer-review journal
So, they have to get into a decent place to make a mark

Do you think that will happen ?
What do you think has to happen in order for ?

It’ll happen, in, in time
They can’t keep refusing you
We, we try again and again
——————————————————————
But in time they just want to, not focus on it, and just have’m, bring in more numbers, and keep doing this, and in the meantime keep treating, some number of patients
On, on, top of everything, my personal belief is, uh, brain tumors are not, uh, a money-raising factor, because it’s a, it’s a minority cancer
If this were treating, uh, mainstream cancers as they’re called, as, uh, breast cancer, maybe they would look at it more seriously, but the numbers, with the brain tumors, which is a good thing
I mean it’s a deadly cancer
You don’t want more people to have it, but, that puts it in the category of, um, you know, not so feasible, as far as the money-making
And so, the priority; even though, it’s the most vicious, and it should be looked at more seriously, but, it’s not the one that brings the big bucks

So

So, put it aside

So why would the FDA, haven’t closed him down then ?

Because they, they, uh, believe the data that he’s sending them so far, and they don’t have a valid point to, just say no, it doesn’t work, and put it away
They see effect, and so they want, more numbers, more data

Is it, it the phase 2 trial is finished ?

Mhmm

but they’re still accepting people ?

Yeah

on more like a special ?

Special basis, and, um, sometimes compassionate grounds

(compassion exception)

Uh, exceptions

That’s normal ?

Yes
So

(Yes I guess it is a funding issue ?)

Right

(Like FDA, during the 2nd phase of clinical trials they found the data to be, real, real one, and they gave him the ok to go for 3rd phase of clinical trials, but just to go through this process you would probably need $100,000)

(?) and that’s stalling

(even more, millions dol, millions of dollars, to go through the 3rd phase of clinical trials, and)

(?)

(he’s a single doctor
It’s a 1st case)

Yeah

(probably in American history)

It is

(that single doctor is trying, to get a his job)

Self-funded

(approval
Self-funded
Whatever you’ve seen on that plant, everything came out of his practice
So he was the one who funded, literally the, the, research and development phase, but those installation, operation, all this big plant was built ?)

Yes, ’cause, uh,

(private)

one of the things I hear a lot, I’ve heard slot in the U.K. is that: “Why is he charging people for clinical trials ?

Well, uh, how else would you run this place ?

Exactly
How will you run this place, and how else will people be on the trial, because

Right

you know, there’s no pharmaceutical company involved here, right ?

There’s nothing
Nothing
It’s all out of his pocket
Every single bit
So
And what is stalling (?) is (?) again is, is funds
Money

Yeah, I also heard that the phase 3 they wanna do radiotherapy with, with it

Mmm

Hopefully, that will not be the case, but

we’re trying to
I think, uh, he is trying to fight against that, but, the FDA is the FDA, so

And what do you think about this case, he’s now got coming up in April ?
You know, he’s got this court case

Well there’s always something

Yeah (laughing)

He, he’s won before, so

Yeah

Do you think he needs the support, do you think he feels the support from, from all of you ?

I think so, for sure

(Oh, absolutely)

Yeah

Nobody forced us to work here

(Ah-hah)

Yeah

We get paid, but, you know
I could always look for another job if I needed to (laugh)

Yeah
So would you stay here because you really believe in what’s going on here ?

(?)

(Yes, that’s one thing that’s unique about our operation, and I’m talking about this location is, uh, whoever joined the company; and we have a guys who joined the company in the 80’s, 90’s
They stay with the company
Turnover is zero)

Yeah

(Joined the company
Stays with the company
It’s a challenge)

Yeah

(It’s a (?) challenge for us)
======================================

======================================